What is the average price target for ENVIVA INC (EVA) stock?
8 analysts have analysed EVA and the average price target is 4.08 USD. This implies a price increase of 871.89% is expected in the next year compared to the current price of 0.4198.
NYSE:EVA • US29415B1035
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ENVIVA INC (EVA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-11-21 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2023-11-16 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2023-11-10 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2023-11-10 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2023-10-18 | JP Morgan | Maintains | Neutral -> Neutral |
| 2023-10-04 | Truist Securities | Maintains | Sell -> Sell |
| 2023-10-03 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2023-10-03 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2023-07-11 | Citigroup | Maintains | Buy -> Buy |
| 2023-05-15 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2023-05-05 | Raymond James | Maintains | Strong Buy |
| 2023-05-04 | Truist Securities | Downgrade | Buy -> Sell |
| 2023-04-05 | Raymond James | Maintains | Strong Buy |
| 2023-04-05 | Citigroup | Maintains | Buy |
| 2023-04-04 | Truist Securities | Maintains | Buy |
| 2023-04-04 | Citigroup | Maintains | Buy |
| 2023-03-03 | JP Morgan | Maintains | Neutral |
| 2023-03-02 | Raymond James | Maintains | Strong Buy |
| 2023-02-01 | Truist Securities | Maintains | Buy |
| 2022-11-29 | RBC Capital | Maintains | Sector Perform |
| 2022-10-20 | JP Morgan | Maintains | Neutral |
| 2022-10-18 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2022-10-14 | Citigroup | Upgrade | Neutral -> Buy |
| 2022-09-15 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2022-08-19 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 875.1M 27.86% | 1.042B 19.04% | 1.094B 5.05% | 1.212B 10.76% | 1.321B 8.99% | 1.799B 36.18% | 1.93B 7.28% | |
| EBITDA YoY % growth | 146.6M 47.63% | 5.9M -95.98% | 26.3M 345.76% | 101.35M 285.36% | 129.2M 27.48% | 198.84M 53.90% | 246.89M 24.17% | |
| EBIT YoY % growth | 69.1M 44.86% | -87M -225.90% | -86.9M 0.11% | -126.25M -45.28% | 1.01M 100.80% | 26.26M 2,500.00% | 32.32M 23.08% | |
| Operating Margin | 7.90% | -8.35% | -7.94% | -10.42% | 0.08% | 1.46% | 1.67% | |
| EPS YoY % growth | 1.08 33.33% | -0.41 -137.93% | -1.80 -339.54% | -4.47 -148.20% | -1.58 64.70% | -0.92 41.42% | -2.04 -120.77% |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.77 -2.75% | -0.63 63.59% | -0.46 25.80% | -0.46 59.73% | -0.45 42.14% | -0.50 19.44% | -0.38 18.33% | -0.17 63.81% | -0.11 75.99% |
| Revenue Q2Q % growth | 311.81M 30.30% | 306.22M 13.80% | 351.53M 16.44% | 389.31M 21.42% | 421.63M 35.22% | 420.11M 37.19% | 473.14M 34.59% | 452.9M 16.33% | 452.91M 7.42% |
| EBITDA Q2Q % growth | 34.84M -48.99% | 15.15M 208.99% | 34.744M -39.05% | 48.278M -46.83% | 56.762M 62.92% | 22.153M 46.22% | 47.686M 37.25% | 65.537M 35.75% | 67.675M 19.23% |
| EBIT Q2Q % growth | -1.01M 97.75% | -22.22M 54.28% | -5.202M 34.98% | 8.484M 173.77% | 13.534M 1,440.00% | -21.21M 4.55% | 4.04M 177.67% | 41.41M 388.10% | 74.74M 452.24% |
All data in USD
8 analysts have analysed EVA and the average price target is 4.08 USD. This implies a price increase of 871.89% is expected in the next year compared to the current price of 0.4198.
ENVIVA INC (EVA) will report earnings on 2024-10-30, after the market close.
The consensus EPS estimate for the next earnings of ENVIVA INC (EVA) is -0.77 USD and the consensus revenue estimate is 311.81M USD.
The expected long term growth rate for ENVIVA INC (EVA) is 11.72%.